Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Hearing Loss × Chemoradiotherapy × Clear all

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Conditions

Rectal Neoplasms 34 Esophageal Neoplasms 17 Carcinoma, Non-Small-Cell Lung 16 Squamous Cell Carcinoma of Head and Neck 15 Nasopharyngeal Carcinoma 10 Pancreatic Neoplasms 9 Head and Neck Neoplasms 9 Uterine Cervical Neoplasms 8 Oropharyngeal Neoplasms 8 Esophageal Squamous Cell Carcinoma 6 Neoplasms 5 Lung Neoplasms 5 Carcinoma, Squamous Cell 5 Urinary Bladder Neoplasms 4 Stomach Neoplasms 4 Mouth Neoplasms 4 Glioblastoma 4 Colorectal Neoplasms 4 Carcinoma 4 Adenocarcinoma 4 Pathologic Complete Response 3 Laryngeal Neoplasms 3 Hypopharyngeal Neoplasms 3 Breast Neoplasms 3 Thymoma 2 Resectable Esophageal Cancer 2 Radiation Injuries 2 Neoplasms by Site 2 Nasopharyngeal Neoplasms 2 NSCLC 2

Interventions

sodium thiosulfate 3 ebselen 2 Ankle Brachial Index 2 Acetylcysteine 2 Tomography, X-Ray Computed 1 Sodium Chloride 1 Saline Solution 1 Ringer's Lactate 1 Radiotherapy 1 Radiosurgery 1 Platinum 1 Ofloxacin 1 Magnetic Resonance Spectroscopy 1 Magnetic Resonance Imaging 1 Hyaluronic Acid 1 Hearing Tests 1 Hearing 1 Genetic Association Studies 1 Ear Protective Devices 1 Drug Therapy 1 Cisplatin 1 Chemoradiotherapy 1 Carboplatin 1 Audiometry, Pure-Tone 1 Atorvastatin 1 Acoustic Impedance Tests 1 1,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06551857 2025-04-16

CaSPiN

Turku University Hospital

Ototoxicity, Neoplasms, Hearing Loss, Cognitive Dysfunction

Data powered by HemOnc (CC BY 4.0) Colophon ⚡